Recent Updates
Recently added Catalysts

FAI Insert

Phase 3

Posterior Uveitis | Small molecule | Ophthalmology |EyePoint, Inc.|Last Updated: Jul 21, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindSHAM_CONTROLLEDBiomarker
Total Trials1
Total Enrollment153
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02746991Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior UveitisPHASE3 COMPLETED 153Jun 2, 2015Oct 4, 2019Jul 21, 202015 India
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months
6 Months

Proportion of Subjects with Recurrence of Uveitis in the Study Eye within 6 Months Including Reason for Imputed Recurrence (ITT Population)

Secondary Endpoints
Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months
36 Months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Sham InjectionSHAM_COMPARATORSham Injection
FAI InsertEXPERIMENTALFAI Insert (0.18 mg fluocinolone acetonide)
Interventions
NameTypeDescription
Sham InjectionDRUGPlacebo
FAI InsertDRUGFluocinolone Acetonide
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites15

Inclusion Criteria: * Male or non pregnant female at least 18 years of age at time of consent * One or both eyes having a history of recurrent non-infectious uveitis affecting the posterior segment of the eye with or without anterior uveitis \> 1 year duration * At the time of enrollment (Day 1), s...

Countries:India
Unlock Eligibility Criteria